2015
First-line treatment and outcome of elderly patients with primary central nervous system lymphoma (PCNSL)—a systematic review and individual patient data meta-analysis
Kasenda B, Ferreri A, Marturano E, Forst D, Bromberg J, Ghesquieres H, Ferlay C, Blay J, Hoang-Xuan K, Pulczynski E, Fosså A, Okoshi Y, Chiba S, Fritsch K, Omuro A, O'Neill B, Bairey O, Schandelmaier S, Gloy V, Bhatnagar N, Haug S, Rahner S, Batchelor T, Illerhaus G, Briel M. First-line treatment and outcome of elderly patients with primary central nervous system lymphoma (PCNSL)—a systematic review and individual patient data meta-analysis. Annals Of Oncology 2015, 26: 1305-1313. PMID: 25701456, PMCID: PMC4735103, DOI: 10.1093/annonc/mdv076.Peer-Reviewed Original ResearchConceptsKarnofsky performance scoreElderly PCNSL patientsFirst-line therapyHD-MTXIndividual patient dataPCNSL patientsImproved survivalEligible studiesElderly primary central nervous system lymphoma (PCNSL) patientsPrimary central nervous system lymphoma (PCNSL) patientsPrimary central nervous system lymphomaSystematic reviewCentral nervous system lymphomaHigh-dose methotrexatePatient dataWhole brain radiotherapyFirst-line treatmentNervous system lymphomaStrong prognostic factorElderly patientsImmunocompetent patientsProspective trialMedian ageOral chemotherapyPrognostic factors
2014
Methotrexate re-challenge for recurrent primary central nervous system lymphoma
Pentsova E, DeAngelis LM, Omuro A. Methotrexate re-challenge for recurrent primary central nervous system lymphoma. Journal Of Neuro-Oncology 2014, 117: 161-165. PMID: 24481997, PMCID: PMC5256683, DOI: 10.1007/s11060-014-1370-0.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntimetabolites, AntineoplasticCentral Nervous System NeoplasmsDisease ProgressionDisease-Free SurvivalFemaleFollow-Up StudiesHumansKaplan-Meier EstimateMaleMethotrexateMiddle AgedNeoplasm Recurrence, LocalPrognosisRetreatmentRetrospective StudiesSalvage TherapyTreatment OutcomeConceptsPrimary CNS lymphomaKarnofsky performance scoreProgression-free survivalInitial diagnosisRecurrent primary central nervous system lymphomaPrimary central nervous system lymphomaMedian Karnofsky performance scoreMedian progression-free survivalCentral nervous system lymphomaObjective response rateNervous system lymphomaMedian OSCNS lymphomaFree survivalRecurrent diseaseSalvage treatmentFirst relapsePartial responsePCNSL patientsPrognostic factorsComplete responseMedian ageSystem lymphomaDisease relapseMedian time
2013
Rituximab, Methotrexate, Procarbazine, and Vincristine Followed by Consolidation Reduced-Dose Whole-Brain Radiotherapy and Cytarabine in Newly Diagnosed Primary CNS Lymphoma: Final Results and Long-Term Outcome
Morris PG, Correa DD, Yahalom J, Raizer JJ, Schiff D, Grant B, Grimm S, Lai RK, Reiner AS, Panageas K, Karimi S, Curry R, Shah G, Abrey LE, DeAngelis LM, Omuro A. Rituximab, Methotrexate, Procarbazine, and Vincristine Followed by Consolidation Reduced-Dose Whole-Brain Radiotherapy and Cytarabine in Newly Diagnosed Primary CNS Lymphoma: Final Results and Long-Term Outcome. Journal Of Clinical Oncology 2013, 31: 3971-3979. PMID: 24101038, PMCID: PMC5569679, DOI: 10.1200/jco.2013.50.4910.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntibodies, Monoclonal, Murine-DerivedAntineoplastic Combined Chemotherapy ProtocolsCentral Nervous System NeoplasmsChemoradiotherapyCranial IrradiationCytarabineDisease-Free SurvivalFemaleHumansLymphomaMaleMethotrexateMiddle AgedProcarbazineRituximabTimeTreatment OutcomeVincristineConceptsProgression-free survivalMedian progression-free survivalMedian overall survivalPrimary CNS lymphomaOverall survivalR-MPVComplete responseCNS lymphomaMedian Karnofsky performance scoreMulticenter phase II studyLong-term disease controlEnd pointApparent diffusion coefficientExploratory end pointsKarnofsky performance scorePhase II studyPrimary end pointWhole brain radiotherapyLong-term outcomesWhite matter changesHigh response rateInduction chemotherapyStandard WBRTBrain radiotherapyII study
2012
Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma
Omuro A, Chan TA, Abrey LE, Khasraw M, Reiner AS, Kaley TJ, Deangelis LM, Lassman AB, Nolan CP, Gavrilovic IT, Hormigo A, Salvant C, Heguy A, Kaufman A, Huse JT, Panageas KS, Hottinger AF, Mellinghoff I. Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma. Neuro-Oncology 2012, 15: 242-250. PMID: 23243055, PMCID: PMC3548585, DOI: 10.1093/neuonc/nos295.Peer-Reviewed Original ResearchConceptsKarnofsky performance scoreProgression-free survival ratesBevacizumab-naive patientsRecurrent malignant gliomaPhase II trialMalignant gliomasII trialPrimary endpointSurvival rateContinuous low-dose temozolomideMedian Karnofsky performance scoreLow Karnofsky performance scoreAdvanced malignant gliomaLow-dose temozolomideMedian overall survivalHalf of patientsFurther treatment strategiesMutations of EGFRBevacizumab exposureEligible patientsTemozolomide schedulesMG patientsOverall survivalMedian ageClinical benefit
2005
High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib
Omuro AM, Kris MG, Miller VA, Franceschi E, Shah N, Milton DT, Abrey LE. High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib. Cancer 2005, 103: 2344-2348. PMID: 15844174, DOI: 10.1002/cncr.21033.Peer-Reviewed Original ResearchConceptsNonsmall cell lung carcinomaCentral nervous systemDisease recurrenceLong-term outcomesCell lung carcinomaBrain metastasesCNS metastasesLeptomeningeal metastasesLung carcinomaHigh incidenceAdvanced nonsmall cell lung carcinomaEpidermal growth factor receptor tyrosine kinase inhibitorsGrowth factor receptor tyrosine kinase inhibitorsMedian Karnofsky performance scoreMemorial Sloan-Kettering Cancer CenterMedian overall survival periodReceptor tyrosine kinase inhibitorsInitial disease recurrenceKarnofsky performance scoreOverall survival periodInitial responseTyrosine kinase inhibitorsInitial siteNeurologic symptomsPartial response